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Abstract Pulmonary distribution and lung functions were evaluated during a 4-month inhaled corticosteroid treat-
ment period in 10 steroid-na|«ve novel asthmatics with normal or slightly reduced lung functions. Patients were given a
totaldailydoseof1000 mgof beclomethasonedipropionate aerosoltwice aday via apressuredmetereddoseinhalerwith
alarge-volumechamberdevice (Volumatic,GlaxoSmithKline,U.K.).Gammalungscintigraphyandlung functiontestswere
performed before and after 2 months and 4 months. Inhaled 99mTc-labelled beclomethasone dipropionate liposomes
wereusedto assesslungdepositionpatternsduringinhaled steroidtherapy.Serumeosinophilcationic protein (ECP) con-
centrationwasusedas a surrogatemarkerof asthmatic inflammation.Followingbeclomethasonetreatment, alllungfunc-
tions were enhanced, but only FVC values showed significant improvement. The FEV1/FVC ratio remained slightly
reduced in spite of inhaled corticosteroid therapy.However, the association between changes in improved FVCvalues
and reduced ECP levels proved to be statistically significant. In lung scintigraphy, no evidence of changes in pulmonary
deposition patternswere seen during the follow-up period.We conclude that inhaled corticosteroid therapy can lead to
improvements in lung functions and surrogate markers of airway inflammation in novel asthma without affecting the
peripheral depositionpattern of aerosols.r2002 Elsevier Science Ltd.Allrights reserved.
Available online athttp://www.sciencedirect.com
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Asthma is regarded as a chronic in£ammatory lung disor-
der in which the in£ammatory process is present in the
whole respiratory tract. Recent evidence shows that in-
£ammation and other pathophysiological changes in the
small airways are important in all stages in asthma (1,2).
There is also evidence of the systemic nature of the dis-
ease (3).
The use of cortisone as an anti-in£ammatory medica-
tion is currently accepted as the standard treatment of
asthma (4). Early introduction of inhaled steroids is now
recommended (5,6) as it may improve lung function (7)
and prevent complications, such as irreversible airwayReceived1July 2002, accepted in revised form 20 July 2002.
Correspondence should be addressed to:Dr. S.Marisanna Saari,
Departmentof RespiratoryMedicine,TampereUniversityHospital,PO
Box 2000, FIN-33521,Tampere, Finland.Fax: +358 3 2473018;
E-mail: marisanna.saari@tays.¢damage or exacerbations (8). The view that asthma is a
systemic disorder would support the use of systemic
therapies (9). The high incidence of severe side e¡ects
from oral corticosteroids have directed their usage pre-
dominately to an inhalation route.To achieve suppression
of the in£ammation throughout the respiratory tract,
treatment should be directed at both large and small
airways. Unfortunately, reduction of the airway caliber
in asthma reduces pulmonary targeting of the inhaled
drug and reduces peripheral drug delivery (10^12).
This raises the questionwhether inhaled corticosteroids
e¡ectively treat the in£ammation present in small
airways.
Pulmonary gamma scintigraphy is a functional
method of evaluating aerosol deposition in the lower air-
ways, aswell as inperipheralparts of the lung.We sought
to evaluate lung deposition patterns of the inhaled aero-
sol during 4 months of inhaled corticosteroid treatment
in novel mild asthmatics, while also studying lung
function values. Peripheral blood eosinophil activity as
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concentration was used as a surrogate marker of
asthmatic in£ammation (13). As a radiolabel we used
99mTc-bound beclomethasone-liposome (DLPC), whose
administration via several di¡erent nebulizers (14),
tolerance (15) and pulmonary deposition in healthy (16)
and asthmatic subjects (10) have been demonstrated
previously.
MATERIALSANDMETHODS
Subjects studied
Ten adult non-smoking steroid-na|«ve patientswith novel,
mild asthma were included in an open before-and-after
trial. All patients had normal or slightly reduced lung
functions, baseline FVC and FEV1measured immediately
prior to the study as 94 and 83% of predicted, respec-
tively.The mean age of the subjects was 33 years (range
19^51 years). Asthma diagnoses were based on clinical
evaluation by the pulmonary phycisian and ful¢lled the
criteria de¢ned by the AmericanThoracic Society (17),
with the addition of an increase in FEV1415% following
a brochodilation test (the inhalation of 200mg of salbuta-
mol). All patients hadnewlydiagnosed asthmawith ahis-
tory of asthma symptoms (cough, wheeze or decreased
tolerance to exercise) during the preceding month at
least. They were recruited to the study from the
outpatient clinic of the Department of Pulmonary
Diseases of Tampere University Hospital. An upper viral
infection within 4 weeks of the start of the experiment
was an exclusion criterion. Moreover, patients with
a signi¢cant pulmonary or cardiac disease were
excluded.
Patients were given 4 months’ inhaled corticosteroid
(ICS) treatment of beclomethasone dipropionate (Beco-
tide 250mg/dose,GlaxoSmithKline,U.K.) with a daily to-
tal dose of 1000mg.Two doses of corticosteroid aerosol
were administered twice a day via a pressurized
metered dose inhaler (MDI) with a large-volume
spacer device (Volumatic,GlaxoSmithKline,U.K.). Spiro-
metric measurements (Vitalograf, Buckinham, U.K.)
were performed and serum ECP samples taken
always at the same time of day at the beginning
(baseline), and after 2 months and 4 months of ICS ther-
apy. In the lung function test, at least three technically
correct maneuvers for forced maximal expiratory £ow
volume curves were performed, and the curve with
the greatest sum of FEV1 and FVC was utilized to
obtain data.
The study was conducted according to the Declara-
tion ofHelsinki.Written, informedconsentwas obtained
from all subjects, and the study protocol was ap-
provedby the Ethical Committee of Tampere University
Hospital.Liposome preparation and labelling of
Bec-DLPC liposomeswith 99mTc
Beclomethasone dipropionate (Bec) and dilauroylpho-
sphatidylcholine (DLPC) liposomes were produced as
previously described by Waldrep (18). Brie£y, 1mg Bec
and 25mgDLPCwere dissolved in10-ml t-butanol. After
mixing, the Bec-DLPC solution was pipetted into glass
vials, rapidly frozen in dry ice^acetone and lyophilized
overnight to remove the organic solvent. The liposome
suspension was produced by adding ultra-pure water to
obtain a ¢nal drug concentration of 500mg/ml.The mix-
turewas stirred for 30min at 371C to allow hydration of
the liposomes.
The preformed Bec^DLPC liposomes were labelled
withTc in the presence of SnCl2 as a reducing agent. In
the preparation of a stannous chloride solution, it is im-
portant to exclude the possibility of oxidation of tin to
the non-reactive stannic form.Therefore, before dissol-
ving stannous chloride (67mg), 100ml of sterile, pyro-
gen-free water was bubbled 30 min with nitrogen in
order to expel most of the oxygen. One milliliter of Tc
pertechnetate in sterile salineFwith a radioactivity of
approx. 780MBq (21mCi)F was then added, and the
mixture (total volume 2.5ml) was shaken vigorously for
1min and left to react at room temperature for 30min.
Labelling e⁄ciency was determinedby paper chroma-
tography (ITCL-SG, prod. 61885, Gelman Sciences, Ann
Arbor, MI, U.S.A.). Free pertechnetate migrates to the
top of the paper, while liposomally entrapped material
remains at the application point. The labelling yield was
expressed as a percentage of the total amount of radio-
activity applied in the testing system. Aerosol character-
istics as well as assessment of 99mTc attachment to the
Bec^DLPC liposome are described in more detail pre-
viously by the author (10,19).
Corticosteroid^liposome delivery
TheTc-labelled Bec^DLPC suspension was delivered by
Aerotech II nebulizers (CIS-US, Bedford, U.S.A.) con-
nected to an automatic, inhalation-synchronized dosi-
meter (Spira Elektro 2, Respiratory Care Center,
HOmeenlinna, Finland). This dosimeter is triggered by a
very low inspiratory £ow rate with a threshold ofo2 l/
min (20,21).The volume of each inhalation is displayed di-
gitally, and the inhalation £owrate is controlledby a £ow
indicator. A breath-actuated, variable-time circuit regu-
lates air through a solenoid valve to a nebulizer, set at a
£owrate of10 l/min.Thevolume output of the dosimeter
with 0.5 s nebulization periods under these operating
conditions is 7ml/breath 70.5. In this study, the dosi-
meter was set to start nebulization at the beginning of
inhalation after the patient had inhaled a volume of
10ml, with each inhalation lasting approximately 3.0 s.
154 RESPIRATORYMEDICINEA total dose of 500mg Bec within the labelled lipo-
somes (2.5ml) was placed in the jet nebulizer. Subjects
were instructed to place the nebulizer tightly between
their lips and inhale deeply.With a noseclip and mouth-
piece in place, the subject controlled breathing with a
£ow indicator (an LED screen) so that the inspiratory
£ow rate of each breath reached but did not exceed
30 l/min. Inhalation was followed by normal exhalation.
Exhaled Bec^liposomes were captured using a Hudson
¢lter. This inspiration procedure was repeated 20 times
according to the subject’s own inspiratory cycle with no
holding of breath between inhalations.Nebulization was
practiced by each subject with saline before the experi-
ment began.
Gamma camerameasurements
Immediately after inhalation, anterior and posterior
views of the lungs and an anterior view of the orophar-
ynx were measured in a supine position by a large ¢eld
gamma camera (GE,CamStarXR/T,WIU.S.A.) equipped
with a low-energy high-resolution parallel collimator. In
order to evaluate the retention of the inhaled liposomes,
scanswererepeated1, 2,4 and 24h after aerosoldelivery.
In addition, a posterior ventilation scan was obtained
after the liposome study by inhaling noble gas 133Xewith
a radioactive dose of 460MBq (12.5mCi). All images
were stored on a computer (Hermes, Nuclear Diagnos-
tics, HOgersten, Sweden) for subsequent data analysis.
133Xe posterior images were used when regions of inter-
est (ROI) were manually drawn around central and per-
ipheral (P) lung zones. ROIs were subsequently
superimposeduponeach liposome aerosol view, enabling
the quantity of aerosol dose in each of the zones to be
determined. Each image was manually aligned, i.e. each
lung view was shifted to adapt to the superimposed
ROIs. The lungs were divided into inner and outer re-
gions, with the central zone encompassing 33% (72%)
and outer the remaining of the total lung area (22,23).
Lung distribution of the liposome aerosol was described
as the ratio between central and peripheral lung areas
(C/P ratio).The total lung retention curvewas described
as a plot of the percentage of initial lung burden vs. time
after inhalation.
The number of counts and pixels in each region of in-
terest was measured and saved to a ¢le in the Hermes
computer. Subsequently, the data were transferred via a
local area network to a personal computer and analyzed
with a program specially made for this study. Counts
from the anterior and posterior views of the lungs were
combinedby taking geometricmeanvalues.The camera-
to-patientdistancewas standardizedby placing the colli-
mator close to the chest for the anterior view and in
contact with the imaging bed for the posterior view.
Geometric mean counts were corrected for the room’sbackgroundFmeasured separately fromeach imageF
and for radioactive decay.
An approximate tissue absorption correctionwas car-
ried out by using the method described by Macey and
Marshall (24). Brie£y, individual transmission images of
each subject’s lung region were taken prior to the lipo-
some studyusing a £atradiation source, keeping the ima-
ging geometry similar both in transmission and
ventilation scans.This transmission method was used to
correct the individual emission counts recordedwith the
gamma camera.
Statistical analyses
Data are expressed as mean7SD unless stated other-
wise. Lung function variables weremeasured before and
during the treatment. Gamma camera measurements
were performed before and during treatment at 0, 1, 2,
4 and 24h after inhalation. For C/P ratios the area under
curve (AUC 0^4h) valueswere calculated for baseline, 2
months and 4 months, and were analyzed by using the
analysis of variance for repeatedmeasurements.For lung
function variables and C/P ratio variables at 0h and 24h
the within-patient changes from baseline to 4 months
were analyzedusing thepaired t-test andwere described
as meanwith 95% con¢dence intervals. Spearman’s rank
correlations were calculated to test the association be-
tween the changes in the lung functions vs.C/P ratio.
RESULTS
All tenpatients completed the study.Daily asthma symp-
toms (wheezing, dyspnea, excess mucus production)
were reduced in all patients with no need for additional
asthma medication.
The main lung function parameters as well as serum
ECP concentrations at the baseline and after each treat-
mentperiod are shown inTable1.Baseline forcedvital ca-
pacity (FVC) and forced expiratory volume in one
second (FEV1) were 94%711.4 of predicted and
83%711.5 of predicted, respectively. Lung functions in-
creased gradually during the 4-month treatment period.
Themean FVC improvedby 0.20 l (95%CI 0.02^0.38) and
was considered statistically signi¢cant. An increase in
FEV1values (0.24 l)was clinically a relevant improvement,
but statistically proved to be insigni¢cant (P=0.15). The
FEV1/FVC ratio remained quite steady or in fact slightly
reduced in spite of the corticosteroid therapy.
Serum ECP levels tended towards reduction during
ICS therapy but the change was insigni¢cant.Table 2 de-
monstrates the association between changes in lung
function andchanges in serumECP levels.The changebe-
tween reduced ECP levels and improved FVC values
proved to be statistically signi¢cant (P=0.001).
TABLE 1. Lung functions of the asthmatic patients before inhaled steroids, and after 2 and 4 months of treatment
After Change (0^4 months)
Characteristics Baseline 2 months 4 months Mean 95%CI P-value
Mean (7SD)
FVC 4.75 (1.10) 4.88 (1.25) 5.11 (1.09) 0.2 0.02 to 0.38 0.04
FVC % predicted 93.8 (11.4) 96.4 (13.1) 100.3 (12.4) 4.78 1.04 to 8.52 0.02
FEV1 3.53 (0.70) 3.77 (0.84) 3.89 (0.73) 0.24 0.11to 0.59 0.15
FEV1% predicted 83.4 (11.5) 88.5 (9.8) 91.4 (9.5) 6 0.68 to12.68 0.07
FEV1/FVC% 75.4 (9.1) 77.8 (5.6) 77.0 (7.7) 1.13 0.90 to 2.30 0.4
FEF 50% predicted 64.5 (25.4) 74.2 (23.5) 73.3 (26.1) 6.11 9.04 to 21.26 0.38
ECP 16.76 (11.34) 16.17 (11.55) 11.93 (6.33) 5.37 12.86 to 2.12 0.14
TABLE 2. Associationbetweenthe changesbetween S- ECPand lung functions during 4 months therapyon inhaled steroids
Change in S-ECP vs.Change in Spearman’s rho P-value
FVC 0.934 0.001
FVC % ofthe predicted 0.587 0.126
FEV1 0.619 0.102
FEV1% ofthe predicted 0.491 0.217
FVC/ FEV1% 0.048 0.911
FEF 50% 0.108 0.799
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FIG. 1. C/Pratio as a function oftime innovel asthmatics during 4 months inhaled steroid therapy and inhealthy volunteers.
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olabelled liposome particles are demonstrated in Fig. 1.
Immediately after inhalation, the ratio between central
and peripheral deposition (C/P ratio) in mild asthmatics
prior to the anti-in£ammatory therapy was 0.7770.10;
after the 4-monthmedication period, 0.7870.13.There-
after, pulmonary distribution patterns remain similarduring the 24-h follow-up period being 0.6970.06 and
0.6770.06 at 24h, respectively. No statistically signi¢-
cant changes in pulmonary deposition patterns were ob-
served in the follow-up period. The AUC (0^4h) values
for C/P ratios were 2.9670.38, 2.9670.29 and
2.9270.37 at baseline, 2 and 4 months (time e¡ect
P=0.93, ANOVA for repeatedmeasurements).
156 RESPIRATORYMEDICINEDISCUSSION
Asthma is a chronic in£ammatory disease characterized
by airway obstruction of varying degrees and bronchial
hyperresponsiveness. Asthmatic in£ammation is now
known to be present in the small airways in addition to
the large and intermediate size airways (25).The e⁄cacy
of inhaled corticosteroid treatment of asthma is well
documented (26), with national and international asthma
guidelines recommending their use as a ¢rst choice ther-
apy.Corticosteroids are usually administrated by inhala-
tion via a metered dose inhaler (MDI) aerosol with a
large-volume spacer or in dry powder (DPI) form. Evi-
dence from both bronchial biopsy tissue and BAL sam-
ples shows that certain in£ammatory markers are
increased in both large and small airways in asthma, and
that anti-in£ammatory treatment should be directed at
both large and small airways to achieve suppression in in-
£ammation throughout the entire respiratory tract (1).
However, not all MDI or DPI inhalers are e⁄cient en-
ough to deposit medication in the peripheral airways of
the lung (11,27,28).Ventilation scans show that in asthma a
greater aerosol deposition occurs in central than in per-
ipheral airways (29,30) and this central accumulation in-
creases with the severity of asthma (10).
Present methods for assessing in£ammation and ob-
struction in peripheral airways are limited. No reliable
direct or surrogate markers for airway in£ammation
are so far available. Standard lung function tests focus
more on large airway events; improvements in these
parametersmay notbe re£ectedby small airway pathol-
ogy (31). Pulmonary gamma scintigraphy provides a func-
tional method of evaluating aerosol deposition in small
airways provided that the inhalation mode and aerosol
particle size are bene¢cial for peripheral lung penetra-
tion (32). In our study, the jet nebulizer (Aerotech II)
was chosen for aerosol delivery because it produces
aerosol particles likely to produce an alveolar deposition
of the inhaledliposomes (MMAD approximately 2mm).In
addition, a slow inspiratory £ow rate was used to mini-
mize impaction in the upper parts of the respiratory
tract.
In earlier studies we demonstrated the e⁄cacy of in-
haled radiolabelled-DLPC liposomes in assessing regio-TABLE 3. C/Pratio inhealthysubjects andinmildandsevere as
Subjects C/ P ratio
Healthy 0.66
Mild asthmatics 0.77
0.78
Mild asthmatics on ICS 0.87
0.77
Severe asthma on ICS 1.07nal lung distribution by means of the C/P ratio at
di¡erent stages of asthma and in healthy subjects. Lung
deposition with DLPC^liposome aerosols produced by
the Aerotech II nebulizer immediately after inhalation
proved tobeuniform throughout the lung tissue,yielding
a central vs. peripheral deposition ratio of 0.66 (19) in
healthy subjects.Central deposition is increased in asth-
ma and enhanced by the severity of the disease.The C/P
ratio di¡ers between severe andmild asthmatic patients
at1.07 and 0.76, respectively (10). In our recent study (33),
we assessed the lung deposition of Bec^DLPC lipo-
somes in chronic stable asthma. Patients had normal or
slightly reduced lung functionwith no asthma symptoms.
A1-week treatment of inhaled formoterol was added to
their regular corticosteroid therapy and lung scintigra-
phy was repeated before and after treatment. Formo-
terol enhanced peripheral lung deposition and thus
lowered the C/P ratio, which was 0.87 at the baseline.
After long-actingbeta2-therapy, theC/P ratio decreased
to 0.77F the same fractional lung distribution as in our
novel asthmatic group of the present study. As a sum-
mary, the data concerning the regional distribution of
Tc-labelled DLPC liposomes is given inTable 3.
In the current study, steroid-na|«ve asthmatic patients
with normal or slightlyreduced lung functionswere trea-
ted for 4 months with inhaled corticosteroids. Clinical
asthma symptoms expired in all patients.Therewas a sig-
ni¢cant improvement in FVC in associationwith a reduc-
tion in concentration of serum ECP.Other lung function
values also improved, except a slightlyreduced FEV1/FVC
ratio present before the corticosteroid therapy, which
may indicate a minor peripheral obstruction resistant
to the administered anti-in£ammatory therapy. In pul-
monary scintigraphy no evidence of change in peripheral
aerosol deposition was demonstrated. Whether this is
due to a lack of in£ammatory control resulting from in-
su⁄cient peripheral deposition of inhaled corticoster-
oids is still an open question.
Recent studies suggest that theparticle size of inhaled
steroids is critical at the delivery site in airways (34). Se-
venty percent of the particles emitted from a standard
chloro£uorocarbon (CFC)-MDI are larger than 5mm
(35). Even with an optimal inhalation technique, only
about 10% of the corticosteroid dose generated bythmaticsmeasuredusing technetium- labelledDLCPliposomes
Before ICS
After ICS
Before therapy
After1-week formoterol therapy
INHALEDCORTICOSTEROIDAEROSOL ANDPERIPHERALLUNGDEPOSITION 157CFC-based inhalers reaches the lower respiratory tract,
with mostmedication deposited in the oropharynx (32).
Esmapour et al. (36) investigated the deposition pattern
of £uticasone dipropionate administered via a large vo-
lume spacer as a single dose.Their study revealed £utica-
sone concentrations three to four times lower in
peripheral airways than in central airways. Although we
are aware of the intersubject and intrasubject variability
of the pulmonary deposition studies (32,37) our results
correspond well with previously mentioned data. Small
airwaysmay be undertreated even inmild asymptomatic
asthmatics. Recent ¢ndings with extra-¢ne hydro£uor-
oalkaline (HFA)-propelled corticosteroid aerosols sug-
gest that these newer small particle formulations have
resultedinbetter peripheral lungdeposition and areduc-
tion in the number of asthma exacerbationsF even at
the lower doses of inhaled corticosteroids F than
CFC-propelled steroids (27,38). The downside of en-
hanced peripheral drug targeting may be an increase in
side e¡ects due to the increased absorption of inhaled
drugs by lung tissue and a resultant increased systemic
bioavailability of the drug.
In conclusion, the knowledge concerning drug delivery
to the small airways is still relatively limited.Our results
correspond to recently published data that the relatively
large particle size of inhaled steroids using conventional
chloro£uorocarbon (CFC)-MDImight leave the small air-
ways undertreated and thereby obstructed due to ine⁄-
cient drug targeting in peripheral lung regions.
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